Trade Mark Journal No.2026/015 10 April 2026

UK00004363412 27 March 2026 (5)

RIVILY

International priority date claimed: 17 November 2025 (United States of America) (99500953)

Class 5: Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss.

Axsome Therapeutics, Inc.

Representative: Keltie LLP